Epoxide hydrolases (EH) are a component of every living thing. A 120 kDa dimer of two identical, 62.5 kDa monomers arranged in an anti-parallel manner makes up the mammalian soluble epoxide hydrolase (sEH). The liver, kidneys, brain, endothelium, and to a lesser extent other tissues, express it most prominently. Many disease states have significant components of inflammation and pain. Blood pressure, inflammation, and pain are all decreased by mammalian sEH inhibition. The down-regulation of COX2 transcription caused by NF-B, which results in less production of pro-inflammatory prostaglandins like PGE2 and PGD2, is a contributing factor in the anti-inflammatory activities of sEH inhibitors.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V51413 | (Rac)-EC5026 ((Rac)-BPN-19186) | 1809885-55-9 | (Rac)-EC5026 ((Rac)-BPN-19186) is an example of a potent soluble epoxy hydrolase (sEH) with a Ki of 0.06 nM. |
|
V99807 | (±)10(11)-EpDPA | 895127-65-8 | (±)10(11)-EpDPA is a metabolite of docosahexaenoic acid epoxidase and can serve as a substrate for soluble epoxide hydrolase (sEH) with a Km value of 5.1 µM for human sEH. |
|
V84657 | 10,11-EDT | 2763501-00-2 | |
|
V112302 | 4H-Tomentosin | 68776-19-2 | 4H-Tomentosin is a mixed competitive inhibitor of soluble epoxide hydrolase (sEH) with an IC50 of 6.84 μM and a Ki of 7.02 μM. |
|
V11535 | AR-9281 | 913548-29-5 | AR-9281 is a novel and potent inhibitor of soluble epoxide hydrolase (s-EH) that can be potentially used for the treatment of hypertension and type 2 diabetes. |
|
V116553 | BRP-821 | BRP-821 is a soluble epoxide hydrolase (sEH) inhibitor with an IC50 value of 0.4 nM. | |
|
V94884 | DJ-53 | DJ-53 (Compound 68) is an orally active phenylquinoline-based soluble epoxide hydrolase inhibitor. | |
|
V37609 | EC-5026 (BPN-19186) | 1809885-32-2 | EC5026 (BPN19186) is a novel, first-in-class, potent and orally bioabailable inhibitor of soluble Epoxide Hydrolase (sEH). |
|
V87415 | Epoxykynin | 640263-95-2 | Epoxykynin is a potent epoxide hydrolase (sEH) inhibitor. |
|
V84770 | FZQ-21 | ||
|
V2720 | GSK2256294A | 1142090-23-0 | GSK2256294A (also known as GSK-2256294) is a novel, potent, selective inhibitor of recombinant human, rat and mouse sEH (Soluble epoxide hydrolase) (IC50 = 27 pM) with the potential to be used for endothelial dysfunction or abnormal tissue repair, such as diabetes, wound healing or COPD. |
|
V104764 | Hydroxytyrosol 1-O-glucoside | 76873-99-9 | Hydroxytyrosol 1-O-glucoside (Dopaol glucoside) is a glycoside with antioxidant activity. |
|
V93293 | LQ-38 | LQ-38 is an orally available soluble epoxide hydrolase (sEH) inhibitor with IC50 of 5.2 nM. | |
|
V120206 | PROTAC sEH-degrader-3 | 3093413-94-3 | PROTAC sEH degrader-3 (compound 1a) is a PROTAC-targeting sEH degrader that selectively degrades sEH in the cytoplasm without affecting sEH in the peroxisome. |
|
V115646 | PROTAC sEH-degrader-4 | PROTAC sEH-degrader-4 is a highly efficient PROTAC degrader that targets the soluble epoxide hydrolase sEH (pDC50 = 10.3). | |
|
V87416 | S-NEPC | 147349-28-8 | S-NEPC (4-Nitrophenyl-2S,3S-epoxy-3 phenylpropyl carbonate) is a colorimetric substrate used to measure the activity of epoxide hydrolases. |
|
V51410 | sEH inhibitor-1 | 1208549-68-1 | sEH Inhibitor-1 (Compound TCPU) is a potent surface-active soluble epoxide hydrolase (sEH) with IC50 of 0.4 and 5.3 nM in human and mouse, respectively. |
|
V79455 | sEH inhibitor-10 | sEH inhibitor-10 (compound 37) is a selective soluble epoxide hydrolase (sEH) inhibitor (IC50=0.5 μM). | |
|
V79775 | sEH inhibitor-11 | sEH inhibitor-11 (compound 35) is an inhibitor (blocker/antagonist) of sEH with IC50 of 0.3 μM. | |
|
V79776 | sEH inhibitor-12 | sEH inhibitor-12 (compound 34) is an inhibitor (blocker/antagonist) of sEH with IC50 of 0.7 μM. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
